We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Alan
Lobo
alan.lobo@nhs.net
Prof
Alan
Lobo
alan.lobo@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Noninfective enteritis and colitis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The AWARE-IBD project is funded by the Health Foundation’s Common Ambition programme. Common Ambition aims to improve access to and quality of care, especially for those whose needs are not being met, by involving members of the public in the design of healthcare. These are the global aims of the AWARE-IBD project.
The University of Sheffield (TUoS) are working with Crohn’s and Colitis UK and local partners in Sheffield to re-design IBD services, shaped by those who use them – people with Inflammatory Bowel Disease (IBD). We aim to put patients with Crohn’s Disease or Ulcerative Colitis, the two main forms of IBD, in control of their care by: 1) co-designing a structure to tell care teams what matters to them; and 2) making that visible in multidisciplinary care team meetings and patient consultations, to optimise care.
To do this, TUoS will be working in partnership with:
• Sheffield Teaching Hospitals NHS Foundation Trust
• Sheffield Microsystems Coaching Academy (MCA)
• EpiGenysys
• Crohn’s and Colitis UK
• VoiceAbility
The Sheffield MCA will steer service improvements through the established Dartmouth approach. This uses a current state analysis, followed by rapid improvement cycles to implement, measure, and sustain improvements. To put patients in control of their care, MCA will train two patients from the Sheffield IBD service as MCA coaches, leading the microsystem, with other service users contributing alongside healthcare professionals.
The research evaluation will show how, and by how much, putting patients in control of their care improves outcomes. TUoS will design a web survey system to collect patient-reported data on the effects of the service changes. Data will be collected using a validated symptoms score, the IBD Control questionnaire, and a patient-reported experience measure (PREM), developed by expert patients. Semi-structured interviews with clinicians and service users will investigate how acceptability and sustainability of the changes.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Other;
You can take part if:
You may not be able to take part if:
1. Participants aged below the age of 16 years 2. Participants who are unable to provide informed consent 3. Significant language barriers, which are likely to affect the participant’s understanding of the study, or the ability to complete outcome questionnaires 4. Participants who are unable to comply with the study protocol
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Alan
Lobo
alan.lobo@nhs.net
Prof
Alan
Lobo
alan.lobo@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST and funded by THE HEALTH FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 50148
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
